Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study).

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Add to Saved list
  • Additional Information
    • Source:
      Publisher: Springer Science + Business Media Country of Publication: United States NLM ID: 9712133 Publication Model: Print Cited Medium: Internet ISSN: 1573-3254 (Electronic) Linking ISSN: 10907165 NLM ISO Abbreviation: AIDS Behav Subsets: MEDLINE
    • Publication Information:
      Publication: 2005- : New York, NY : Springer Science + Business Media
      Original Publication: New York, NY : Plenum Press, 1997-
    • Subject Terms:
      Homosexuality, Male*; Adenine/*analogs & derivatives ; Anti-HIV Agents/*administration & dosage ; Antiviral Agents/*administration & dosage ; Deoxycytidine/*analogs & derivatives ; HIV Infections/*prevention & control ; Health Services Accessibility/*statistics & numerical data ; Organophosphonates/*administration & dosage ; Pre-Exposure Prophylaxis/*methods; Adenine/administration & dosage ; Adenine/economics ; Adult ; Anti-HIV Agents/economics ; Antiviral Agents/economics ; California ; Deoxycytidine/administration & dosage ; Deoxycytidine/economics ; Emtricitabine ; Health Expenditures ; Health Knowledge, Attitudes, Practice ; Health Surveys ; Humans ; Male ; Middle Aged ; Organophosphonates/economics ; Patient Acceptance of Health Care ; Pre-Exposure Prophylaxis/economics ; Pre-Exposure Prophylaxis/statistics & numerical data ; Tenofovir ; Unsafe Sex/psychology
    • Abstract:
      Tenofovir-emtricitabine (TDF-FTC) has demonstrated effectiveness as HIV preexposure prophylaxis (PrEP), but it is not commonly prescribed. Our study was designed to determine the barriers preventing utilization of PrEP among men who have sex with men (MSM), the group at greatest risk for HIV infection in the United States. A population-based sample of MSM presenting for HIV testing at 'Early Test' HIV testing and counseling sites in San Diego, California were offered PrEP and education about potential efficacy. Eligible individuals reported having unprotected sex within the past 12 months and who tested negative for HIV were offered study participation. Despite offering procedures for evaluation and prescription for PrEP to 416 eligible subjects, less than 0.5 % of participants received the drug. Surveys collected from 54 of those who declined study participation revealed multiple barriers to PrEP among MSM including cost, low perceived risk of infection and concerns about taking a daily medication and potential long-term side effects. Efforts should be made to address these barriers, especially lowering the cost of TDF-FTC, education about PrEP side effects and awareness of HIV risks.
    • References:
      N Engl J Med. 2012 Aug 2;367(5):423-34. (PMID: 22784038)
      AIDS Behav. 2013 Jul;17(6):2173-9. (PMID: 23128980)
      N Engl J Med. 2010 Dec 30;363(27):2587-99. (PMID: 21091279)
      Sci Transl Med. 2012 Sep 12;4(151):151ra125. (PMID: 22972843)
      AIDS Patient Care STDS. 2013 Apr;27(4):248-54. (PMID: 23565928)
      MMWR Morb Mortal Wkly Rep. 2011 Jan 28;60(3):65-8. (PMID: 21270743)
      Curr Opin HIV AIDS. 2012 Nov;7(6):593-9. (PMID: 23032736)
      N Engl J Med. 2012 Aug 2;367(5):399-410. (PMID: 22784037)
      AIDS Patient Care STDS. 2012 Feb;26(2):87-94. (PMID: 22149764)
      Sex Transm Infect. 2013 May;89(3):207-11. (PMID: 23015689)
    • Grant Information:
      P01 AI080193 United States AI NIAID NIH HHS; K24 AI100665 United States AI NIAID NIH HHS; R21 AI077304 United States AI NIAID NIH HHS; AI043638 United States AI NIAID NIH HHS; R01 AI047745 United States AI NIAID NIH HHS; AI36214 United States AI NIAID NIH HHS; MH083552 United States MH NIMH NIH HHS; R21 AI047745 United States AI NIAID NIH HHS; GM093939 United States GM NIGMS NIH HHS; R01 GM093939 United States GM NIGMS NIH HHS; U01 AI043638 United States AI NIAID NIH HHS; R56 AI047745 United States AI NIAID NIH HHS; MH62512 United States MH NIMH NIH HHS; U19 AI096113 United States AI NIAID NIH HHS; AI090970 United States AI NIAID NIH HHS; R24 AI106039 United States AI NIAID NIH HHS; UM1 AI069432 United States AI NIAID NIH HHS; AI080193 United States AI NIAID NIH HHS; AI080353 United States AI NIAID NIH HHS; AI047745 United States AI NIAID NIH HHS; U01 AI069432 United States AI NIAID NIH HHS; AI74621 United States AI NIAID NIH HHS; T32 AI007384 United States AI NIAID NIH HHS; DP1 DA034978 United States DA NIDA NIH HHS; R21 AI080353 United States AI NIAID NIH HHS; DA034978 United States DA NIDA NIH HHS; P30 MH062512 United States MH NIMH NIH HHS; P30 AI036214 United States AI NIAID NIH HHS; AI100665 United States AI NIAID NIH HHS; R01 MH083552 United States MH NIMH NIH HHS; AI007384 United States AI NIAID NIH HHS; AI077304 United States AI NIAID NIH HHS; U19 AI090970 United States AI NIAID NIH HHS; AI69432 United States AI NIAID NIH HHS; P01 AI074621 United States AI NIAID NIH HHS; AI096113 United States AI NIAID NIH HHS
    • Accession Number:
      0 (Anti-HIV Agents)
      0 (Antiviral Agents)
      0 (Organophosphonates)
      0W860991D6 (Deoxycytidine)
      99YXE507IL (Tenofovir)
      G70B4ETF4S (Emtricitabine)
      JAC85A2161 (Adenine)
    • Publication Date:
      Date Created: 20140715 Date Completed: 20150126 Latest Revision: 20220321
    • Publication Date:
      20221216
    • Accession Number:
      PMC4127131
    • Accession Number:
      10.1007/s10461-014-0845-5
    • Accession Number:
      25017425